X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AMAR REMEDIES with LINC PEN &PL - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs LINC PEN & PLASTICS LTD - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES LINC PEN & PLASTICS LTD AMAR REMEDIES/
LINC PEN & PLASTICS LTD
 
P/E (TTM) x -0.5 37.6 - View Chart
P/BV x 0.1 6.7 0.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 AMAR REMEDIES   LINC PEN & PLASTICS LTD
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
LINC PEN & PLASTICS LTD
Mar-16
AMAR REMEDIES/
LINC PEN & PLASTICS LTD
5-Yr Chart
Click to enlarge
High Rs164243 67.6%   
Low Rs86136 63.2%   
Sales per share (Unadj.) Rs261.6232.7 112.4%  
Earnings per share (Unadj.) Rs17.412.4 140.4%  
Cash flow per share (Unadj.) Rs22.316.4 135.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs100.768.4 147.3%  
Shares outstanding (eoy) m26.1614.79 176.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.50.8 58.7%   
Avg P/E ratio x7.215.3 47.0%  
P/CF ratio (eoy) x5.611.5 48.6%  
Price / Book Value ratio x1.22.8 44.8%  
Dividend payout %024.2 0.0%   
Avg Mkt Cap Rs m3,2702,800 116.8%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m163186 87.8%   
Avg. sales/employee Rs ThNM5,167.3-  
Avg. wages/employee Rs ThNM278.8-  
Avg. net profit/employee Rs ThNM275.1-  
INCOME DATA
Net Sales Rs m6,8443,441 198.9%  
Other income Rs m217 284.6%   
Total revenues Rs m6,8653,449 199.1%   
Gross profit Rs m1,131314 360.3%  
Depreciation Rs m12860 214.6%   
Interest Rs m39815 2,601.3%   
Profit before tax Rs m626246 254.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m12163 191.5%   
Profit after tax Rs m455183 248.4%  
Gross profit margin %16.59.1 181.2%  
Effective tax rate %19.325.6 75.4%   
Net profit margin %6.65.3 124.9%  
BALANCE SHEET DATA
Current assets Rs m4,9041,334 367.7%   
Current liabilities Rs m3,581802 446.7%   
Net working cap to sales %19.315.5 125.0%  
Current ratio x1.41.7 82.3%  
Inventory Days Days12482 151.6%  
Debtors Days Days10051 197.9%  
Net fixed assets Rs m1,689437 386.2%   
Share capital Rs m262148 177.2%   
"Free" reserves Rs m2,358863 273.1%   
Net worth Rs m2,6351,011 260.6%   
Long term debt Rs m5070-   
Total assets Rs m6,8621,855 370.0%  
Interest coverage x2.617.1 15.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.01.9 53.8%   
Return on assets %12.410.7 116.2%  
Return on equity %17.318.1 95.3%  
Return on capital %31.025.9 119.8%  
Exports to sales %4.027.9 14.3%   
Imports to sales %016.0 0.0%   
Exports (fob) Rs m273959 28.5%   
Imports (cif) Rs mNA552 0.0%   
Fx inflow Rs m273960 28.4%   
Fx outflow Rs m2577 0.3%   
Net fx Rs m271383 70.7%   
CASH FLOW
From Operations Rs m-31397 -322.6%  
From Investments Rs m-489-185 264.5%  
From Financial Activity Rs m76974 1,037.5%  
Net Cashflow Rs m-33-14 236.5%  

Share Holding

Indian Promoters % 25.5 60.4 42.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 9.2 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 39.6 164.9%  
Shareholders   13,061 6,688 195.3%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   EMAMI LTD  ARCHIES LTD  GILLETTE INDIA  P&G HYGIENE  GODREJ CONSUMER  

Compare AMAR REMEDIES With:   P&G (US)  UNILEVER PLC. (UK)  HYPERMARCAS (Brazil)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 5-YR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS